IL156264A0 - Isoindolin-1-one glucokinase activators - Google Patents

Isoindolin-1-one glucokinase activators

Info

Publication number
IL156264A0
IL156264A0 IL15626401A IL15626401A IL156264A0 IL 156264 A0 IL156264 A0 IL 156264A0 IL 15626401 A IL15626401 A IL 15626401A IL 15626401 A IL15626401 A IL 15626401A IL 156264 A0 IL156264 A0 IL 156264A0
Authority
IL
Israel
Prior art keywords
isoindolin
glucokinase activators
glucokinase
activators
diabetes
Prior art date
Application number
IL15626401A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL156264A0 publication Critical patent/IL156264A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
IL15626401A 2000-12-13 2001-12-07 Isoindolin-1-one glucokinase activators IL156264A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25527300P 2000-12-13 2000-12-13
US31871501P 2001-09-13 2001-09-13
PCT/EP2001/014404 WO2002048106A2 (en) 2000-12-13 2001-12-07 Isoindolin-1-one glucokinase activators

Publications (1)

Publication Number Publication Date
IL156264A0 true IL156264A0 (en) 2004-01-04

Family

ID=26944583

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15626401A IL156264A0 (en) 2000-12-13 2001-12-07 Isoindolin-1-one glucokinase activators
IL156264A IL156264A (en) 2000-12-13 2003-06-02 Isoindolin-1-On as glucokinase activators, their preparation process and pharmaceutical preparations

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL156264A IL156264A (en) 2000-12-13 2003-06-02 Isoindolin-1-On as glucokinase activators, their preparation process and pharmaceutical preparations

Country Status (35)

Country Link
US (1) US6482951B2 (https=)
EP (1) EP1349856B1 (https=)
JP (1) JP4021766B2 (https=)
KR (1) KR100520651B1 (https=)
CN (1) CN1247574C (https=)
AT (1) ATE297922T1 (https=)
AU (2) AU2002238415B2 (https=)
BG (1) BG107903A (https=)
BR (1) BR0116169A (https=)
CA (1) CA2430579C (https=)
CY (1) CY1105587T1 (https=)
CZ (1) CZ20031882A3 (https=)
DE (1) DE60111570T2 (https=)
DK (1) DK1349856T3 (https=)
EG (1) EG24358A (https=)
ES (1) ES2243578T3 (https=)
HR (1) HRP20030450B1 (https=)
HU (1) HUP0400587A3 (https=)
IL (2) IL156264A0 (https=)
MA (1) MA26973A1 (https=)
MX (1) MXPA03005170A (https=)
MY (1) MY136741A (https=)
NO (1) NO325810B1 (https=)
NZ (1) NZ526236A (https=)
PA (1) PA8534601A1 (https=)
PE (1) PE20020593A1 (https=)
PL (1) PL366006A1 (https=)
PT (1) PT1349856E (https=)
RS (1) RS50933B (https=)
RU (1) RU2249590C2 (https=)
SI (1) SI1349856T1 (https=)
SK (1) SK8732003A3 (https=)
TW (1) TWI294876B (https=)
UY (1) UY27069A1 (https=)
WO (1) WO2002048106A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
BR0314864A (pt) 2002-10-03 2005-08-02 Novartis Ag Compostos orgânicos
PL375149A1 (en) 2002-10-03 2005-11-28 F.Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
AU2003294376A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7262196B2 (en) * 2003-02-11 2007-08-28 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US7781451B2 (en) * 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
BRPI0509573A (pt) 2004-04-02 2007-09-25 Novartis Ag derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
KR101346902B1 (ko) 2005-07-09 2014-01-02 아스트라제네카 아베 당뇨병 치료에 있어 glk 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체
WO2007026761A1 (ja) * 2005-08-31 2007-03-08 Astellas Pharma Inc. チアゾール誘導体
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
CN101316836A (zh) 2005-11-01 2008-12-03 詹森药业有限公司 作为葡萄糖激酶变构调节剂的取代的二氢异吲哚酮类
EP1951706A1 (en) 2005-11-01 2008-08-06 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
EP1960386A2 (en) * 2005-11-01 2008-08-27 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
CA2627813A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
WO2007051845A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
EP1948614A2 (en) * 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
EP2001875A2 (en) * 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2049518B1 (en) * 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
WO2008074694A1 (en) * 2006-12-20 2008-06-26 F. Hoffmann-La Roche Ag Crystallization of glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
JP5248477B2 (ja) * 2007-03-07 2013-07-31 杏林製薬株式会社 グルコキナーゼ活性化物質
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
TW200934772A (en) * 2008-01-15 2009-08-16 Lilly Co Eli Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide
WO2009092432A1 (en) * 2008-01-24 2009-07-30 Merck Patent Gmbh Beta-amino acid derivatives for treatment of diabetes
KR101608259B1 (ko) * 2008-04-28 2016-04-01 교린 세이야꾸 가부시키 가이샤 시클로펜틸아크릴산아미드 유도체
KR20110018366A (ko) * 2008-05-16 2011-02-23 다케다 샌디에고, 인코포레이티드 글루코키나아제 활성제
AU2009290474A1 (en) * 2008-09-11 2010-03-18 Pfizer Inc. Heteroaryls amide derivatives and their use as glucokinase activators
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
US8178689B2 (en) * 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
US8470866B2 (en) * 2011-05-03 2013-06-25 Hoffmann-La Roche Inc. Isoindolinone derivatives
SI3004076T1 (sl) * 2013-05-27 2020-02-28 F. Hoffmann-La Roche Ag Novi spojini 3,4-dihidro-2H-izokinolin-1-on in 2,3-dihidro-izoindol-1-on
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
CN116283717B (zh) * 2023-01-06 2025-04-08 暨南大学 一种藁本内酯衍生物及其制备方法和应用
WO2024229228A2 (en) * 2023-05-02 2024-11-07 The Rockefeller University 1-oxoisoindolin-2-yl amide activators of vcp and derivatives thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687147A1 (fr) * 1992-02-11 1993-08-13 Union Pharma Scient Appl Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant.
DE69523182T2 (de) * 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
PL350669A1 (en) 1999-03-29 2003-01-27 Hoffmann La Roche Glucokinase activators
AU5227001A (en) 2000-05-03 2001-11-12 Hoffmann La Roche Hydantoin-containing glucokinase activators
DK1282611T3 (da) 2000-05-08 2005-02-14 Hoffmann La Roche Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer

Also Published As

Publication number Publication date
KR20030064817A (ko) 2003-08-02
EG24358A (en) 2009-03-04
CA2430579C (en) 2010-01-26
IL156264A (en) 2010-11-30
US20020082260A1 (en) 2002-06-27
UY27069A1 (es) 2002-07-31
EP1349856B1 (en) 2005-06-15
CA2430579A1 (en) 2002-06-20
NZ526236A (en) 2004-12-24
MXPA03005170A (es) 2003-09-22
NO20032674D0 (no) 2003-06-12
PE20020593A1 (es) 2002-07-06
HUP0400587A3 (en) 2011-03-28
DE60111570T2 (de) 2006-05-11
PT1349856E (pt) 2005-09-30
HUP0400587A2 (hu) 2004-06-28
PA8534601A1 (es) 2002-08-26
KR100520651B1 (ko) 2005-10-11
WO2002048106A2 (en) 2002-06-20
BG107903A (bg) 2004-02-27
CN1481382A (zh) 2004-03-10
BR0116169A (pt) 2003-12-23
CY1105587T1 (el) 2010-07-28
WO2002048106A3 (en) 2002-11-28
HK1063314A1 (en) 2004-12-24
NO20032674L (no) 2003-06-12
RS50933B (sr) 2010-08-31
SI1349856T1 (en) 2005-10-31
MA26973A1 (fr) 2004-12-20
MY136741A (en) 2008-11-28
US6482951B2 (en) 2002-11-19
ATE297922T1 (de) 2005-07-15
NO325810B1 (no) 2008-07-21
AU2002238415B2 (en) 2007-01-04
DK1349856T3 (da) 2005-10-17
CN1247574C (zh) 2006-03-29
JP4021766B2 (ja) 2007-12-12
CZ20031882A3 (cs) 2003-12-17
PL366006A1 (en) 2005-01-24
RU2249590C2 (ru) 2005-04-10
JP2004521095A (ja) 2004-07-15
HRP20030450A2 (en) 2005-04-30
ES2243578T3 (es) 2005-12-01
YU47703A (sh) 2006-05-25
SK8732003A3 (en) 2004-04-06
HRP20030450B1 (en) 2006-02-28
DE60111570D1 (de) 2005-07-21
AU3841502A (en) 2002-06-24
TWI294876B (en) 2008-03-21
EP1349856A2 (en) 2003-10-08

Similar Documents

Publication Publication Date Title
EG24358A (en) Isoindolin-1-one glucokinase avtivators
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
MY135222A (en) Substituted phenylacetamides and their use as glucokinase activators
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
CA2499329A1 (en) Indole-3-carboxamides as glucokinase (gk) activators
MY136926A (en) Glucokinase activators
PT1311504E (pt) Tetrazolil-fenil-acetamidas activadoras da glucoquinase
WO2001083465A3 (en) Alkynyl phenyl heteroaromatic glucokinase activators
JO2180B1 (en) Glucokinase Trans olivine steroids
IL144948A0 (en) Electroactive pore
PT1282611E (pt) Fenilacetamidas substituidas e sua utilizacao como activadores da glucocinase
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
AU2002213925A1 (en) Use of glp-1 and flp-2 peptides for treatment of bone disorders
UA84025C2 (en) Normal;heading 1;heading 2;2-(QUINOXALIN-5-YLSULFONYLAMINO)-BENZAMIDE COMPOUNDS AS CCK2 MODULATORS
MY142777A (en) Substituted indole-o-glucosides
MXPA02008722A (es) Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa.
PT1435991E (pt) Utilização de aplidina para o tratamento de cancro pancreático
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
JO2238B1 (en) Glycine stimulants iswindline 1- on
EP1251847A4 (en) NEW USE OF PRODIGIOSINE TO TREAT DIABETES
MXPA04000418A (es) Tratamiento de dolor cronico con 3-heterocicloxi- y -cicloalquiloxi-3-fenilpropanaminas.
UA42301A (uk) Засіб "камілаль" для лікування і профілактики проктологічних захворювань
UA32466C2 (uk) Комплексний інфузійний препарат "реосорбілакт"
MXPA04003673A (es) Uso de aplidina para el tratamiento de cancer pancreatico.
MD1919G2 (ro) Remediu medicamentos